The roles of VEGF in the pathogenesis of clinical ROP and experimental ROP are well documented, and intra-ocular injection of VEGF inhibitors is the most used therapy for preterm infants with ROP50. The gene discussed is VEGFA; the disease is retinopathy of prematurity.